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Abstract 
Background  Postprocedural aortic regurgitations following transcatheter aortic valve implantation (TAVI) procedures remain an is-
sue. Benefit of oversizing strategies to prevent them isn’t well established. We compared different level of oversizing in our cohort of con-
secutive patients to address if severe oversizing compared to normal sizing had an impact on post-procedural outcomes. Methods  From 
January 2010 to August 2013, consecutive patients were referred for TAVI with preoperative Multislice-CT (MSCT) and the procedures 
were achieved using Edwards Sapien® or Corevalve devices®. Retrospectively, according to pre-procedural MSCT and the valve size, pa-
tients were classified into three groups: normal, moderate and severe oversizing; depending on the ratio between the prosthesis area and the 
annulus area indexed and measured on MSCT. Main endpoint was mid-term mortality and secondary endpoints were the Valve Academic 
Research Consortium (VARC-2) endpoints. Results  Two hundred and sixty eight patients had a MSCT and underwent TAVI procedure, 
with mainly Corevalve®. While all-cause and cardiovascular mortality rates were similar in all groups, post-procedural new pacemaker (PM) 
implantation rate was significantly higher in the severe oversizing group (P = 0.03), while we observed more in-hospital congestive 
heart-failure (P = 0.02) in the normal sizing group. There was a trend toward more moderate to severe aortic regurgitation (AR) in the normal 
sizing group (P = 0.07). Conclusions  Despite a higher rate of PM implantation, oversizing based on this ratio reduces aortic leak with 
lower rates of post-procedural complications and a similar mid-term survival. 
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1  Introduction 
Transcatheter aortic valve implantation (TAVI) is the 
standard treatment for old patients suffering from severe 
symptomatic aortic stenosis at high or prohibitive risk for 
surgery.[1,2] Pre-interventional prosthesis sizing relies on 
aortic Multislice-CT (MSCT).[3] Incorrect prosthesis sizing 
may result in adverse outcomes such as moderate-to-severe 
paravalvular aortic regurgitation (AR)[4] and device emboli-
zation in case of undersizing,[5] or aortic root rupture[6] and 
conduction disorders in case of severe oversizing.[7]  Mod-
erate to severe AR has been shown to be an independent 
predictor of mortality[8] and MSCT can predict AR.[9] 
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While some studies suggest that oversizing based on area 
appears to provide the best risk-benefit ratio to reduce post-
procedural regurgitation and conduction disorders,[10] the 
impact of different levels of oversizing of the bioprosthetic 
valve on the aortic annulus is not well understood.[11] Pre-
vious studies report early posprocedural outcomes but im-
pact at 1-year follow-up is unknown.[12] 
The aim of this study was to report the prognostic value 
of different grade of oversizing on the mortality and major 
advert cardiac and cerebral events (MACCE) at 1-year fol-
low-up but also on the post-procedural Valve Academic 
Research Consortium (VARC-2) criteria,[13] and in particu-
lar on aortic regurgitation. 
2  Methods 
Between January 2010 and August 2013, consecutive pa-
tients undergoing TAVI procedure at our institution were 
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included in a dedicated prospective database. All patients 
had severe symptomatic aortic valve stenosis (indexed aor-
tic valve area < 0.6 cm2/m2) and multiple comorbidities. The 
institutional multidisciplinary heart teams agreed each pa-
tient should proceed to TAVI. All patients gave written in-
formed consent for the procedures. 
Patients’ clinical characteristics on admission and during 
follow-up were collected prospectively. All patients under-
went transthoracic echocardiography (TTE), coronary an-
giography, and aortic MSCT, allowing us to determine the 
most suitable access. Selection of the bioprosthesis, Ed-
wards SAPIEN (Edwards Lifesciences, Irvine, CA, USA), 
or Medtronic Corevalve (Medtronic Inc, Minneapolis, MN, 
USA) was determined following aortic root assessment us-
ing MSCT. 
2.1  Pre- and post-procedural echocardiography 
Comprehensive echocardiography was performed before 
and after TAVI procedure using commercially available 
Vivid® 7 or 9 (General Electric Healthcare, USA) or a 
iE33® (Phillips Medical, The Netherlands), to determine 
annulus diameter as well as to assess general parameters 
like pressure gradients, mitral valve, and left ventricular 
function. AR was reported as recommended in the VARC 2 
guidelines (regarding the circumferential extent of pros-
thetic valve paravalvular regurgitation: mild < 10%, moder-
ate 10%29%, and severe > 30%). 
2.2  Pre procedural MSCT. 
We used electrocardiographically synchronized (gated) 
imaging of the aortic root, to avoid motion-induced artifacts. 
Reconstruction of the annulus was performed orthogonally 
in relation to the central axis of the left ventricular outflow 
tract; to analyze minimal and maximal diameters, circum-
ference, and area (Figure 1). Other parameters were also 
assessed (heights and width of sinus of valsalva, ascending 
aorta diameters, calcifications, and septum thickness). We 
used a commercially available and dedicated post process-
ing software (Philips Medical, Eindhoven, The Netherlands; 
Trimensio® GmBh).  
Retrospectively, according to pre-procedural MSCT and 
implanted prosthesis size, patients were classified into three 
groups depending on the ratio between the prosthesis area 
(diameter × diameter × π) and the annulus area indexed on 
the body surface area and measured on the preprocedural 
MSCT (Figure 1). Group 1 was the “Normal sizing group 
(NS)” with a ratio between 1 and 2, Group 2 was the “Mod-
erate oversizing group (MO)” with a ratio between 2.1 and 
2.5, Group 3 was the “Severe oversizing group (SO)” with a 
ratio between 2.6 and 4. 
 
Figure 1.  MSCT assessment of annular dimensions (area, 
short and long diameters). MSCT: MultiSlice-CT. 
2.3  TAVI procedure 
Standard TAVI implantation technique was followed as 
previously described.[14] Procedures were performed in a 
hybrid operative theatre by a multidisciplinary team includ-
ing anesthesiologists, interventional cardiologists and car-
diac surgeons. Patients systematically underwent general 
anesthesia. Per procedural heparin (0.5 mg/kg) was injected 
immediately before valve insertion. Deployment of the 
prosthesis was performed through different access, includ-
ing femoral, subclavian, carotid, and transapical access. In 
case of post-deployment angiography showing AR ≥ 2/4, a 
balloon post-dilation was performed. Significant regurgita-
tions were also sought out through a final control TEE. In 
case of endovascular procedure, the sheath was removed 
and the access site closed surgically or thanks to percutane-
ous closure system. 
2.4  Endpoints 
The clinical endpoints were defined according to stan-
dardized criteria proposed by the Valve Academic Research 
Consortium updated in 2012 (VARC-2). 
The primary endpoints of interest were the 1-year (1) 
global and (2) cardiovascular mortalities.  
Secondary endpoints included long-term survival (rang-
ing from four months to four years) and MACCE at one 
year  (composite of all-cause mortality, major stroke, and 
myocardial infarction).  
Further analyses explored cerebrovascular events (major 
stroke, minor stroke, transient ischemic attack), myocardial 
infarction (MI), bleeding (life-threatening and major), acute 
renal failure, access site complications (major and minor), 
and new pace-maker implantation. 
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2.5  Statistical analysis 
Statistical analysis was performed by using commercial 
software (SAS 9.3; SAS Institute, Cary, NC, USA). Results 
for continuous variables were expressed as means with 
standard deviations when data were symmetrically distrib-
uted or, otherwise, as medians with ranges. The normality of 
distribution was assessed using Shapiro-Wilk test and nor-
mality diagrams. Results for categorical variables were ex-
pressed as frequencies and percentages.  
Comparative analyses were obtained using the chi-square 
test for categorical data; when not applicable because of the 
sample size, the Fisher’s exact test was used. For numerical 
variables, we used the ANOVA test or Kruskal-Wallis test 
if normality of distribution was not present.  
Survivals were calculated by the Kaplan-Meier method, 
and the differences between groups were compared using 
the log-rank test. P values < 0.05 were considered statisti-
cally significant. 
3  Results 
Between January 2010 and August 2013, n = 268 con-
secutive patients with severe symptomatic aortic valve 
stenosis were prospectively enrolled in this observational 
study.  
The baseline demographic, clinical, and echocardio-
graphic characteristics of the study population are listed in 
Table 1. 
The mean patient age was 80.6 ± 7.2 years and most 58% 
(n = 156) were female. The average Society of Thoracic 
Surgeons predicted risk of mortality (STS Prom) score was 
6.7% ± 4.8%. There were few differences between the SO 
group  and the two others regarding BMI (P < 0.001), STS 
score (P = 0.03) and smaller annulus diameter (P < 0.001). 
Indeed our ratio is calculated with a annulus area indexed on 
the body surface (STS score take BMI into account).  
3.1  Procedural outcomes 
General anesthesia was performed in all cases. We had 
no valve embolization or aortic root rupture. N = 201 (75%) 
Corevalve® devices and n = 67 (25%) Edwards Sapien® 
heart valve were implanted. We used more Corevalve® de-
vices in the SO group than in the other two groups (P < 
0.001). The series included 7 (2%) cases where a tran-
scatheter valve was placed inside a failing aortic bioprosthe-
sis (P = 0.87).  
3.2  Post-procedural outcomes 
There was a similar in-hospital mortality between groups,  
Table 1.  Baseline characteristics of the three groups.  
 
NS 
(n = 89) 
MO    
(n = 89) 
SO 
(n = 90) 
Overall
P Value
Clinical characteristics     
Age, yrs 82.0 ± 8.1 79.9 ± 7.1 80.1 ± 6.6 0.12 
Sex, female 60 (67%) 47 (52%) 49 (54%) 0.09 
BMI, kg/m2 23.5 ± 3.7 26.8 ± 5.6 29.7 ± 6.2#$ < 0.001*
Euroscore 2, % 5.7 ± 5.0 6.4 ± 7.1 5.9 ± 6.9 0.74 
STS score,% 7.7 ± 5.4 6.6 ± 4.7 5.8 ± 4.3#$ 0.03* 
Diabetes 22 (25%) 27 (30%) 25 (27%) 0.73 
COPD 21 (23%) 23 (25%) 29 (32%) 0.40 
NYHA class IV 35 (39%) 26 (29%) 26 (29%) 0.23 
Pre procedural PM  10 (11%) 14 (15%) 15 (16%) 0.54 
Prior TIA-Stroke 16 (18%) 14 (15%) 10 (11%) 0.40 
Prior AF 34 (38%) 39 (43%) 41 (45%) 0.58 
Prior renal failure  48 (54%) 51 (57%) 48 (53%) 0.84 
Prior Balloon  
Valvuloplasty  
5 (5%) 5 (5%) 9 (10%) 0.44 
Prior CABG 10 (11%) 16 (18%) 14 (15%) 0.44 
TTE characteristics - - - - 
LVEF, % 53.2 ± 14.7 55.2 ± 13.9 56.8 ± 13.4 0.23 
MaxV, m/s 4.33 ± 0.77 4.24 ± 0.67 4.31 ± 0.57 0.69 
Aortic valve area, cm2/m2 0.43 ± 0.23 0.39 ± 0.11 0.37 ± 0.12 0.34 
AR moderate to severe 2 (2%) 2 (2%) 0 (0) 0.35 
MSCT characteristic - - - - 
Annulus diameter, mm 25.4 ± 2.9 24.3 ± 2.8 23.7 ± 2.5#$ < 0.001*
Data are presented as mean ± SD or n (%). *P < 0.05; #SO vs. NS, P < 0.05; 
$SO vs. MO, P < 0.05. AF: atrial fibrillation: BMI: body mass index, CABG: 
coronary artery bypass graft; COPD: chronic obstructive pulmonary disease; 
LVEF: left ventricular ejection fraction; MaxV: maximal velocity; MO: 
Moderate oversizing group; MSCT: MultiSlice-CT; NS: Normal sizing 
group; NYHA: New York Heart Association; Preproc AR: pre-procedural 
aortic regurgitation; PM: pace maker; STS: Society of Thoracic Surgeons; 
SO: Severe oversizing group; TIA: transient ischemic attack; TTE 
transthoracic echocardiography. 
 
n = 19 (7%) (P = 0.10). We found a significant increase in 
cardiovascular death in the NS group compared to the MO 
and SO groups (P = 0.04). After one month, MACCE oc-
curred more frequently in the NS group (P = 0.009). Major 
bleeding and major vascular complications occurred respec-
tively in 5 (2%) and 18 (6%) patients, with no difference 
between groups. Cerebrovascular events (transient ischemic 
attack-TIA and stroke) occurred in 18 patients (6%). New 
permanent pacemaker was required in 58 (21%), mostly 
with self-expanding devices (86%). There was also signifi-
cantly more new pace maker implantation in the SO group 
than in the NS group (P = 0.02). Twenty-nine (10%) pa-
tients presented moderate to severe post-procedural aortic 
regurgitation assessed by TTE, with a significant difference 
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between SO and NS groups (P = 0.03). Aortic regurgita-
tions were similar between Corevalve and Edwards Sapien 
devices (P = 0.70). No prosthesis thrombosis, endocarditis 
or other valve-associated complications were observed. 
Post-implantation hemodynamics demonstrated a reduction 
in transvalvular mean gradient from 42.4 ± 10.1 to 7.5 ± 2.0 
mmHg (P < 0.001) and an increase in the effective orifice 
area from 0.80 ± 0.32 cm2 to 1.74 ± 0.33 cm2 (P < 0.001) 
with no difference between groups. There were 20 (7%) 
cases of new onset atrial fibrillation, at the same rate in the 
three groups (P = 0.98).  
Interestingly we found more intra hospital-CHF in the 
NS group (P = 0.02). No significant differences between the 
3 groups were observed in the incidence of other VARC- 
defined complications (Table 2). 
3.3  Follow-up: mortality and morbidity 
Thirty-days mortality was 9% (n = 24) with a significant  
Table 2.  Procedural and in-hospital outcomes.  
 
NS    
(n = 89) 
MO    
(n = 89) 
SO    
(n = 90)
Overall
P value
Procedural characteristics - - - - 
Predilation 83 (93%) 86 (96%) 81 (91%) 0.30 
Postdilation 16 (18%) 17 (19%) 16 (18%) 0.98 
Femoral access 61 (68%) 60 (67%) 56 (62%) 0.63 
Carotid access 12 (13%) 20 (22%) 22 (24%) 0.15 
Bioprosthesis diameter, mm 26.8 ± 2.1 27.5 ± 2.1 28.3 ± 1.5#$ < 0.001*
Corevalve® device  53 (59%) 66 (74%) 82 (91%)#$ < 0.001*
Postprocedural outcomes - - - - 
New PM implantation 11 (12%) 23 (25%) 24 (26%)# 0.03*
MI 2 (2%) 1 (1%) 0 (0) 0.10 
TIA-Stroke 6 (6%) 4 (4%) 8 (9%) 0.53 
CHF 11 (12%) 12 (13%) 3 (3%)#$ 0.02*
AKI stage 2-3 34 (38%) 34 (38%) 33 (36%) 0.97 
Major and minor vascular 
complications 
22 (25%) 25 (28%) 23 (25%) 0.29 
All bleedings 25 (28%) 15 (28%) 24 (27%) 0.98 
Hospital stay duration, days 12.5 ± 6.4 14.1 ± 8.4 13.5 ± 9.4 0.44 
ICU stay duration, days 3.1 ± 3.9 2.6 ± 4.0 3.0 ± 7.4 0.81 
Postprocedural TTE - - - - 
AR moderate-severe 15 (15%) 8 (8%) 6 (6%)# 0.07 
MaxV, m/s 2.01 ± 0.46 2.06 ± 0.52 2.15 ± 0.49 0.20 
AVA, cm2/m2 1.66 ± 0.41 1.75 ± 0.47 1.82 ± 0.46 0.16 
Data are presented as mean ± SD or n (%). *P < 0.05; #SO vs. NS, P < 0.05; 
$SO vs. MO, P < 0.05. AKI: acute kidney injury; AVA: aortic valve area; 
CHF: congestive heart failure; ICU: intensive care unit; LT: life-threatening; 
MI: myocardial infarction; MO: Moderate oversizing group; NS: Normal 
sizing group; PM: pace maker; Post-AR: post-procedural aortic regurgita-
tion in angiography; Post-TTE: one week post-procedural transthoracic 
echocardiography; SO: Severe oversizing group. 
increase of mortality in the NS group (P = 0.04) and of car-
diovascular death in the NS group compared to the oversiz-
ing groups (P = 0.04). One-month major advert cardiac and 
cerebrovascular events occurred in 30 patients (11%). We 
observed more MACCE in the NS group than in the SO 
group (P = 0.01). One MI and two transient ischemic at-
tacks occurred in the NS group. We found no other differ-
ences regarding the left and right systolic function (TTE), or 
new late pacemaker implantation between the three groups 
(Table 3). 
Table 3.  One-month outcomes.  
 
NS    
(n = 89) 
MO    
(n = 89) 
SO    
(n = 90)
Overall 
P value
Clinical outcomes - - - - 
30-days mortality 13 (15%) 6 (7%) 5 (5%)# 0.08
30-days MACCE 16 (18%) 9 (10%) 5 (5%)# 0.03*
NYHA class III-IV 5 (6%) 7 (9%) 6 (7%) 0.87
TTE characteristics - - - - 
AR moderate to severe 12 (19%) 7 (10%) 5 (7%) 0.31
MaxV, m/s 1.91 ± 0.46 1.97 ± 0.51 2.03 ± 0.46 0.35
AVA, cm2/m2 1.76 ± 0.48 1.78 ± 0.50 1.77 ± 0.49 0.97
Data are presented as mean ± SD or n (%). *P < 0.05; #SO vs. NS, P < 0.05. 
AR: aortic regurgitation; AVA: aortic valve area; MACCE: major advert 
cardiac and cerebral event; MaxV: maximal velocity; MO: Moderate over-
sizing group; Ns: non-significant; NS: Normal sizing group; NYHA: New 
York Heart Association; TTE; transthoracic echocardiography; SO: Severe 
oversizing group. 
 
MACCE (n = 42, 15%) at 1-year occurred at the same 
rate between the three groups (P = 0.92). One-year global (n 
= 50, 18%) and cardiovascular mortalities (n = 39, 14%) 
were similar in the three groups; P = 0.52 and P = 0.32, 
respectively (Figures 1 and 2).  
4  Discussions 
The impact of different levels of oversizing isn’t well  
understood as it can have positive and side effects on valve 
implantation and post-procedural outcomes and long-term 
implications are not known.[15] 
This observational study with consecutive patients series 
evaluate retrospectively the prognostic value of an index 
reflecting accurately different levels of oversizing on the 
post-procedural outcomes.  
To compare our ratio to previous studies like Blanke, et 
al.[6] were they used the relative difference in diameter be-
tween pre-TAVI MSCT mean annulus diameter and nomi-
nal diameter of the selected prosthesis, we would have, re-
spectively 6.6% ± 10.4% (NS group), 13.6% ± 9.2% (MO); 
20.6% ± 11.4% (SO) with a significant difference  
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Figure 2.  (A) Long-term global mortality; (B) Long-term car-
diovascular mortality. 
P < 0.0001. Calculated as the relative difference in area 
between pre-TAVI MSCT mean annulus area and measured 
valve area of the selected prosthesis, 13.1% ± 17.12% (NS 
group); 28.7% ± 16.7% (MO); 45.8% ± 39.1% (SO) with P 
< 0.0001.  
4.1 Clinical and functional impact 
As Hayashida, et al.[16] described before, MSCT-guided 
valve sizing in TAVI significantly reduces the incidence of 
post-procedural AR compared to TEE sizing, and we tried 
using such a new index to evaluate retrospectively in our 
cohort the reality of this assertion.  
This is the first study to report the impact of different 
levels of oversizing on the 1-year mortality and MACCE. 
We did not observe any differences regarding the global 
mortality or the cardiovascular mortality whatever the type 
of valve, reinforcing the idea that oversizing may be a safe 
and feasible approach in TAVI patients. 
Post-procedural new pace-maker implantation rates were 
significantly higher in the SO group (P = 0.02), while we 
observed more in-hospital congestive heart-failure (P = 0.02) 
in the NS group. We found no aortic root rupture in all 
groups. We found also more moderate to severe AR in the 
NS group (P = 0.03) as previously reported.[9]  
At 1-month the mortality was higher and there was sig-
nificantly more MACCE in the NS group than in the over-
sizing groups. Finally we found no differences about the 
1-year MACCE (P = 0.92) and mortality (P = 0.52). 
As previously found by Leber, et al.[10] aggressive over-
sizing resulted in decreasing significant AR but induced 
conductance disorders requiring pacemaker implantations in 
a significant number of patients. On the other hand, normal 
sizing was associated with a trend toward higher incidence 
of immediate post-procedural AR. 
 The most important finding in the current study is that 
the incidence of early post-operative complications, except 
the pace-maker implantation, seems to be higher in the 
Normal group than in the Oversizing groups, but that bene-
fice tend to fade on the long term with no benefit on the 
global or cardiovascular mortalities. 
4.2 Limitations 
First, this non-randomized study reflects the experience 
of a single center only. We did not compare MSCT to other 
3-dimensional imaging techniques like 3D-TEE or MRI.[17] 
Because this is an MSCT study, the findings may not nec-
essarily be concordant with a TEE study. 
Although the MSCT, echographic and clinical data were 
prospectively collected, this is a retrospective observational 
study and therefore may be subjected to confounding factors, 
especially for the long term follow-up. We mostly used 
Corevalve devices, which are known to provide more com-
plete atrio-ventricular block.[18] 
We didn’t explore the positioning of the valve, which can 
impact also on outcomes. 
Accurate assessment of paravalvular AR is difficult in 
the absence of standardized methods and only relies on 
color flow imaging with direct measures of the number of 
jets and jet size. 
Because of our indexed ratio, we had significantly a 
lower STS score (take BMI into account), more obese, a 
bigger prosthesis size and a smaller MSCT annulus area in 
the oversizing groups. 
4.3 Conclusions 
Despite higher rate of new PM implantation, severe 
oversizing (ratio between bioprosthesis area and the annulus 
area indexed on the body surface measured by MSCT: 2.6 
to 4) reduces postprocedural aortic regurgitation and have 
similar 1-year survival than normal sizing. 
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